Gilead Sciences and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel; axi-cel) for
Cancer immunotherapy is revolutionising oncology – but the Havas Lynx Group’s chief medical officer Vernon Bainton argues that the incredible progress is creating a new
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh